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ABSTRACT
Background: Genomic disorders are often caused by
non-allelic homologous recombination between segmental
duplications. Chromosome 16 is especially rich in a
chromosome-specific low copy repeat, termed LCR16.
Methods and Results: A bacterial artificial chromosome
(BAC) array comparative genome hybridisation (CGH)
screen of 1027 patients with mental retardation and/or
multiple congenital anomalies (MR/MCA) was performed.
The BAC array CGH screen identified five patients with
deletions and five with apparently reciprocal duplications
of 16p13 covering 1.65 Mb, including 15 RefSeq genes.
In addition, three atypical rearrangements overlapping or
flanking this region were found. Fine mapping by high-
resolution oligonucleotide arrays suggests that these
deletions and duplications result from non-allelic homo-
logous recombination (NAHR) between distinct LCR16
subunits with .99% sequence identity. Deletions and
duplications were either de novo or inherited from
unaffected parents. To determine whether these imbal-
ances are associated with the MR/MCA phenotype or
whether they might be benign variants, a population of
2014 normal controls was screened. The absence of
deletions in the control population showed that 16p13.11
deletions are significantly associated with MR/MCA
(p=0.0048). Despite phenotypic variability, common
features were identified: three patients with deletions
presented with MR, microcephaly and epilepsy (two of
these had also short stature), and two other deletion
carriers ascertained prenatally presented with cleft lip and
midline defects. In contrast to its previous association
with autism, the duplication seems to be a common
variant in the population (5/1682, 0.29%).
Conclusion: These findings indicate that deletions
inherited from clinically normal parents are likely to be
causal for the patients’ phenotype whereas the role of
duplications (de novo or inherited) in the phenotype
remains uncertain. This difference in knowledge regarding
the clinical relevance of the deletion and the duplication
causes a paradigm shift in (cyto)genetic counselling.
Non-allelic homologous recombination (NAHR)
between neighbouring intrachromosomal segmen-
tal duplications (also termed low copy repeats, or
LCRs) is the main mechanism underlying genomic
disorders. Several recurrent clinical syndromes are
caused by either gains or losses of sequences
flanked by segmental duplications. Since the initial
discovery that Charcot–Marie–Tooth disease and
HNPP (hereditary neuropathy with liability to
pressure palsies) are caused by the duplication and
the reciprocal deletion at 17p11.2, respectively,
many other recurrent clinical syndromes have been
shown to be caused by NAHR.
1 The finding that
around 4% of the human genome is made up of
intrachromosomal segmental duplicons led to
speculation that many more unrecognised recur-
rent rearrangement syndromes might exist.
2 The
advent of array comparative genome hybridisation
(CGH) has enabled genome-wide screening for
copy number variations (CNVs) in large patient
populations leading to the identification of several
novel low copy repeat-mediated rearrangements.
34
Chromosome 16 is especially rich in intrachro-
mosomal segmental duplications. During recent
primate evolution, chromosome 16 has undergone
intense segmental duplication activity, and . 10%
of the euchromatic region of the p arm is composed
of highly complex low copy repeats.
56 During
evolution, these blocks were generated in a
stepwise fashion, generating multiple subunits
termed LCR16a–t, with a size range of 20–600 kb
and sharing .97% sequence similarity.
7 The com-
plex architecture of chromosome 16p therefore
suggests it as an excellent candidate region for
novel microdeletion syndromes.
3 Recently, Ballif
et al
8 reported a novel microdeletion syndrome of
16p11.2–p12.2, which seems to be mediated by
NAHR between 16p segmental duplicons. In
addition to this novel syndrome, various studies
analysing CNVs inpatients with mentalretardation
and/or multiple congenital anomalies (MR/MCA)
have reported imbalances of 16p13.
9–11 However, the
relevance of these findings remains unclear.
During the screening of 1027 patients with MCA
and/or MR, we identified 6 deletions and 7
duplications of 16p12–p13, apparently caused by
NAHR between LCR16. Our detailed analyses of
these imbalances define 16p13.11 as a region of
recurrent microdeletion/duplication and suggest
that the deletion is a risk factor for MR/MCA
but the clinical relevance of the duplication is
uncertain.
METHODS
Selection of patients
This study involved patients with MR/MCA,
ascertained from three sources: (1) those diagnosed
by the clinical geneticist of Leuven, Belgium
(n=500), (2) children and young adults from a
variety of UK clinical genetics centres, community
learning disability teams and other sources,
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3 and (3) DNA
from autopsies of fetuses with >1 congenital anomalies at
Children’s Hospital and Regional Medical Center (Seattle, WA)
after death or elective termination (n=155).
12 All were reported
to have a normal karyotype at 550 G-band resolution, and in
many cases cryptic subtelomeric rearrangements and other
specific genetic abnormalities had been excluded.
Array comparative genome hybridisation
Patients were analysed using two different bacterial artificial
chromosome (BAC) array CGH platforms. Patient samples from
Leuven, Belgium (n=500) were hybridised to a custom BAC
array with clones spaced at approximately 1 Mb intervals
throughout the genome, according to the protocol of Menten
et al.
13 Regions were scored as CNVs if one clone passed the
threshold of 46the normal standard deviation (SD), and if >2
flanking clones passed the threshold of log2(3/2)226SD.
14
Patient samples from the UK (n=372) and USA (n=155)
were hybridised to a custom BAC array consisting of ,2000
clones targeted to regions of the genome flanked by segmental
duplications.
10 Regions were scored as CNVs if the log2 ratio of
>2 consecutive clones each exceeded 26SD of the autosomal
clones in dye-swap replicate experiments.
3
An additional patient with a 16p13.11 duplication was
identified by array CGH to human 105K genome-wide
oligonucleotide arrays (Agilent Technologies, Diegem,
Belgium) according to the manufacturer’s instructions. In brief,
genomic DNAs from the patient and from a single sex-matched
reference patient were separately double-digested using the
restriction endonucleases AluI and RsaI (Promega, Leiden, The
Netherlands) and purified using Microcon centrifugal filter
devices (Millipore Corporation, Missouri, Minneapolis, USA).
Then 1.5 mg of the digested products were differentially labelled
by random priming with Cy3-dUTP and Cy5-dUTP (Perkin
Elmer, Foster City, California, USA) and cohybridised to the
array for 48 hrs at 65uC in a rotating oven. Parental DNAs were
also hybridised using this method. The hybridised arrays were
washed and scanned (Microarray Scanner; Agilent). Image data
were extracted using Feature Extraction V.8.5 software
(Agilent) and the data analysed using CGH Analytics V.3.4
software (z-score method setting) (Agilent).
To refine thebreakpoints of these rearrangements, we utilised
oligonucleotide arrays. One oligoarray consisting of 385 000
isothermal custom made probes (length 45–75 bp) covering a
number of chromosomal regions, including this 5 Mb region of
chromosome 16p (mean density, 1 probe per 131 bp)
(NimbleGen Systems, Madison, Wisconsin, USA).
Hybridisations were performed as described previously,
15 and
samples from a single normal man were used as the reference
(GM15724; Coriell, Camden, New Jersey, USA).
The second oligoarray used (GeneChip Human Mapping
262K NspI; Affymetrix, Santa Clara, California, USA) contains
262 264 25 oligonucleotides. In this experimenrt, 250 ng geno-
mic DNA was processed according to the manufacturer’s
instructions (Affymetrix GeneChip Human Mapping 500K
Manual; http://www.affymetrix.com). Copy number was
assessed using DNA-Chip Analyzer (dChip) software 2006.
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Regions of copy number gain and loss were found using the
hidden Markov model output of dChip.
Real-time quantitative PCR
Real-time quantitative PCR (qPCR) was performed as pre-
viously described
13 with minor modifications. Primers were
designed from RepeatMasked sequence (www.repeatmasker.
org/) using Primerexpress V.2.0.0 oligo design software (Applied
Biosystems, Lennik, Belgium), and validated with in silico PCR
and genome searching using Blat software (http://genome.ucsc.
edu/). Single-nucleotide polymorphisms (SNPs) were excluded
from the primer sequence (SNP track in UCSC Browser). Real-
time qPCR was performed using a commercial preparation
(Q-PCR MasterMix Plus for SYBR Green I without UNG
(uracil-N-glycosylase); Eurogentec, Liege, Belgium) according to
the manufacturer’s instructions. Each reaction was performed in
duplicate in a final volume of 15 ml containing 6–30 ng/ml
genomic DNA, 1.25 mM forward/reverse primer, and 7.5 ml
SYBR Green mastermix.
Control populations
The first control population comprised 722 unrelated indivi-
duals from Belgium who had been referred for clinical genetic
testing for haemochromatosis or cystic fibrosis. Genomic DNA
of each individual was extracted from blood lymphocytes
according to standard procedures, and assayed by real-time
qPCR using primer pair 3 (Eurogentec, Seraing, Belgium) for
detection of copy number changes of 16p13.1. Thresholds were
set at a fold difference of 0.8 and 1.3. All samples surpassing
these thresholds were analysed twice to confirm the presence of
copy number changes.
A second control population, comprising 960 unrelated
Caucasian adults (age 40–70 years) from the USA, were
genotyped using a chip array (HumanHap300 Genotyping
BeadChips; Illumina, San Diego, California), comprising
,317 000 HapMap SNPs distributed throughout the genome.
Each individual was enrolled in the Pharmacogenomics and Risk
of Cardiovascular Disease (PARC) study, which aims to identify
genetic contributors to the variable efficacy of statin drugs on
cardiovascular disease risk (http://www.pharmgkb.org/do/
serve?objId=5&objCIs=Project). Hybridisations, data analysis
and copy number analysis, focused on this region of 16p, were
performed according to published protocols.
17
CASE REPORTS
Patients carrying 1.65 Mb 16p13.11 deletions
Patient 1 (ID 224725)
This adult patient is the only affected member of five siblings.
She has severe MR, therapy-resistant epilepsy and behavioural
problems. She has short stature (143 cm, less than third
percentile (P3) of 155 cm) and microcephaly (occipitofrontal
circumference (OFC) 51 cm; P3 =52.2 cm). She has a short
nose, smooth philtrum, wide mouth and fine palpebral
fissures. She has difficulty in expressive language and has an
ataxic gait.
Patient 2 (ID 335606)
This adult proband and his brother were referred with severe
MR. The proband has short stature (150 cm; P3 =168 cm),
microcephaly (OFC 51 cm; P3 =52.2 cm), pectus excavatum
and limb spasticity. He is being treated for epilepsy.
Patient 3 (ID 22698)
This adult man with moderate MR is the only child of non-
consanguineous parents. His stature and OFC are normal and
he is obese (103 kg; .P97). He is not dysmorphic, is extremely
talkative, and displays intermittent verbal aggression and
self-mutilation.
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This patient is the male sibling of a dizygotic twin pregnancy
that occurred via in vitro fertilisation with intracytoplasmic
sperm injection (ICSI). At 16 weeks gestation, ultrasound
examination demonstrated abnormalities in the female fetus.
The pregnancy went to term. The male fetus has a ventricular
septal defect (VSD) and a right-sided aorta. He is subject to
frequent infections because of his low CD3 count – he has a
22q11 deletion. The 1856 g cyclopic female fetus had a crown
rump length of 28.5 cm and a head circumference of 26 cm
(proportionally microcephalic). Holoprosencephaly, agenesis of
the nose, a midline upper lip notch and a median cleft palate
were present together with two pre-auricular tags on the left,
and a right dysplastic ear with a pre-auricular tag and an atretic
auditory canal.
Patient 5 (ID FA-180)
Prenatal ultrasound at 18 weeks gestation showed a cleft lip
on the right, a possible intracranial abnormality with dilated
lateral ventricles, and thinning of the cortical mantle. The
pregnancy was terminated at 21 weeks. Autopsy showed post-
haemorrhagic hydrocephalus with marked ventriculomegaly,
cortical thinning, a hypoplastic falx cerebri, cleft lip on the right
side, two preauricular skin tags on the right, and cleft T1 and T3
vertebral bodies. Physical growth parameters were consistent
with gestational age. This patient was reported by Mefford
et al.
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Patients carrying 1.65 Mb 16p13.11 duplications
Patient 6 (ID 325275)
The second child of non-consanguineous parents, this patient
was born after an uneventful pregnancy. He has moderate MR.
He was constipated from birth and at 6 months was diagnosed
with Hirschsprung disease, for which he had a resection and an
end-to-end anastomosis. Behavioural problems developed at
5 years of age and he has received special education. As an adult,
he has normal biometry, bushy eyebrows and a mandibular
overbite.
Patient 7 (ID IMR277)
This patient was originally reported by Kriek et al
9 as part of a
multiplex ligation-dependent probe amplification (MLPA)
screen of 105 patients selected for developmental delay and/or
congenital malformations. He had learning problems in primary
school, but is not clearly dysmorphic and has no serious
behavioural problems. The extent of the duplication was
verified using array CGH and fluorescent in situ hybridisation.
MLPA and real-time qPCR of the parents confirmed the de novo
nature and the size of this duplication.
Patient 8 (ID IMR277)
This patient has severe learning disabilities with limited use of
language, poor vocabulary and repetitive speech. She displays
challenging, agitated behaviour marked by shouting, hand-
clapping, kicking, hitting and throwing objects at people,
although this has improved with age. She has epilepsy.
Patient 9 (ID IMR220)
The patient is the only child of non-consanguineous parents. He
walked at 13 months, and later was described as clumsy but not
dyspraxic. Speech has always been problematic. His delay was
moderate (IQ of 55), and he had behavioural problems such as
increased impulsivity and limited attention control. Grommets
were inserted for upper airway infections, but otherwise there
were no major physical problems. At 14 L years of age, OFC
was 54.7 cm (50th centile). He was noted to have large simple
ears, thick lips, a large tongue, and large and somewhat puffy
hands with small nails. CT scan of the brain was normal.
Metabolic screening of urine showed no abnormalities. EEG was
normal. Ophthalmological examination showed bilateral astig-
matism. Fragile X syndrome (FRAXA) testing showed a full
expansion in the patient and a premutation in his mother,
which had been inherited from her father.
Patient 10 (ID OxP078)
An ultrasonography examination at 20 weeks gestation revealed
microcephaly in this patient. This was confirmed after delivery
and at 4 years of age the OFC was 44 cm (P3=48.6 cm). The
patient had brachycephaly, telecanthus, abnormal eyebrows,
deep-set eyes, epicanthic folds, a pinched nasal tip, prominent
nose and small jaw. She also had a VSD, an umbilical hernia,
deep creases on the palms and soles, and clinodactyly. An MRI
scan showed a small brain with delayed myelination and
prominent extra axial fluid-filled spaces. The patient has
delayed speech and hyperactive behaviour with aggressive
episodes. At 6 years of age, she attends normal school with a
large amount of learning support. The child’s mother also has a
small head, mild learning difficulties and poor temper control.
Her mother (the proband’s maternal grandmother) has a small
head and mild learning difficulties. One developmentally and
behaviourally normal maternal aunt carries the duplication and
one aunt with mild learning difficulties and aggressive
behavioural is cytogenetically normal.
Patients carrying larger atypical 16p13.11 rearrangements
Patient 11 (ID 66529)
The only child of non-consanguineous parents, this patient was
born at term with a birth weight of 3200 g. She had feeding and
respiratory difficulties in the neonatal period. As an adult , she
has an asymmetrical face with left facial nerve paresis, a short
neck with reduced mobility, bilateral epicanthal folds, strabis-
mus, choroid colobomata, and previously had atresia of the
right choana. An atrial septal defect type 2 closed spontaneously
and she has a unique right kidney with double ureters. She has
hearing difficulties, and a CT scan showed aplasia of the
semicircular canals and abnormal middle ear bones. Her
behaviour is normal. CHD7 mutation analysis was normal.
Patient 12 (ID IMR184)
This patient was reported in Sharp et al.
3
Patient 13 (ID 20754)
This sixth child, born to a mother with pre-eclampsia, weighed
1800 g at full term. She had neonatal seizures and marked
developmental delay, not walking and talking until 4 years of
age. As an adult, she has has short stature (150 cm;
P3=155 cm) and microcephaly (OFC 50.5 cm; P3=52.2 cm).
She has an IQ of 38 and has cyclic depression.
RESULTS
Recurrent microdeletion/duplication of 16p13.11
Array CGH was performed on 1027 patients or fetuses with
unexplained MR/MCA using one of two custom BAC
arrays.
10 13 In total, 13 patients with 16p12–p13 rearrangements
were found (1.3%), 6 of whom carried a deletion and 7 a
duplication. Ten of these rearrangements (five deletions and five
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,1.65 Mb region of 16p13.11, suggesting that they probably
represent the reciprocal events of NAHR (fig 1). Three
additional patients carried atypical larger rearrangements.
These were up to 3.4 Mb in size, and either overlapped or
flanked the more common 1.65 Mb 16p13.11 deletions/duplica-
tions seen in the other 10 patients. Real-time qPCR was used to
confirm the results of the array CGH analysis, and clearly
distinguished patients with deletions and duplications from
normal controls (fig 2). For one patient with a typical deletion
(patient 4), testing of parental DNA showed that the micro-
deletion was inherited from the phenotypically normal father.
In contrast, for one patient with a typical duplication (patient
10), testing revealed three generations in which the duplication
initially seemed to segregate with a mild or more severely
abnormal phenotype, but testing of additional family members
showed that the duplication and phenotype did not cosegregate.
Rearrangement breakpoints localise to LCR16 segmental
duplication blocks containing a positively selected gene family
Each rearrangement was mapped at higher resolution using
either 262k NspI SNP arrays (Affymetrix) (fig 3) or a custom
oligonucleotide array (Roche Nimblegen, Madison, Wisconsin,
USA) (fig 4). These data confirmed the results of the BAC array
CGH, and localised the breakpoints of each rearrangement to
segmental duplications composed of large clusters of LCR16.
7
Significantly, patients 1–10 had both proximal and distal
breakpoints that localised to the same intervals (distal break-
points, 14.7–14.75 Mb, proximal breakpoints 16.3–16.77 Mb).
These duplication blocks, which define the common breakpoint
regions, were also found to be strongly polymorphic in copy
number in normal controls (fig. 4, supplementary material
online). These polymorphic breakpoint regions correspond to
LCR16a/LCR16b motifs, which have been shown to have
undergone rapid proliferation during primate evolution and
contain a gene family, Morpheus, which has a signature of
extreme positive selection.
18 Real-time qPCR using primers
flanking these segmental duplications confirmed that that the
breakpoints occurred within these LCRs (fig 2).
There are 15 RefSeq genes in the common 1.65 Mb recurrent
rearrangement region. Given that microcephaly and brain
malformations are the major recurrent characteristic in our
patients with deletions, NDE1 was believed to be a good
candidate for a dosage-sensitive gene that might underlie the
features of these deletions. In order to test the hypothesis that
the deletion acts by unmasking the presence of a recessive
mutation on the remaining allele, we sequenced the NDE1 gene
in four of our patients with deletions (1–4). Primers covering all
eight exons and the 59 and 39 untranslated regions (suppple-
mentary table 1 online) were used for direct sequencing of
genomic DNA, but no mutations were found.
The microdeletion associates with the MR/MCA phenotype
Although neither 16p13.11 duplications or deletions have been
found in 210 unrelated HapMap individuals,
19 nor in 122 other
individuals sampled from the normal population,
10 20 21 a larger
and population matched sample size was needed in order to
draw a statistically meaningful conclusion as to their patho-
genic significance. Therefore, the copy number of the com-
monly rearranged 16p13.1 region in 722 population matched
controls ascertained from the Belgian population, and in a
further 960 Caucasian controls drawn from the USA, were
evaluated. These analyses did not detect any deletions of this
region in the 1682 controls tested, but did reveal the presence of
five 16p13.11 duplications. Although we do not have access to
detailed clinical information for these five controls, the method
used to ascertain them suggests that they are unlikely to have
significant developmental abnormalities, but we cannot exclude
possibility that they might have abnormal learning, memory or
behavioural characteristics. Combining these data with pre-
viously published analysis of 332 controls results in a total
control population of 2014, including 5 carriers of 16p13.1
duplications, but no carriers of deletions. This compares with 5
deletions and 7 duplications ascertained from 1027 patients
with MR/MCA. We therefore conclude that deletions of
16p13.1 are significantly associated with patient phenotype
(p=0.0048, Pearson x
2 test with simulated p value, based on
10 000 replicas), but show incomplete penetrance, as demon-
strated by their presence in some apparently unaffected
relatives. The incidence of duplications in association with
disease is not significantly different from that in controls
(p=0.1273, Pearson’s x
2 test). This observation leads us to a
number of possible conclusions regarding the duplication
including that it might (1) be truly clinically benign, (2) be
Figure 1 Molecular overview of
recurrent deletions and reciprocal
duplications in patients 1–10.
(A) ENSEMBL overview (freeze: 24-04-
2007) which visualises 1 Mb bacterial
artificial chromosome (BAC) clones, the
genes involved in the imbalance, the copy
number variable regions
19 and
chromosome bands. (B) The location of
real-time quantitative PCR primers used
to fine-map the breakpoints, are depicted.
(C) The extent of the deletion and
duplication is shown by red and green
bars, respectively in typical del/dup
patients. (D) Organisation of the
segmental duplication structure at the
distal and proximal breakpoints of
recurrent 16p13.1 rearrangements. Each
coloured bar represents a pairwise
alignment with .98% identity.
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not been excluded) in the control population tested or (3) work
in combination with other predisposing factors to give an MR
phenotype.
Atypical rearrangements of chromosome 16p12–p13
In addition to the common recurrent 1.65 Mb microdeletion/
duplication of 16p13.11 observed in 10 patients, 3 atypical
rearrangements were found. Two patients (11 and 12) carried a
larger duplication of ,3.4 Mb in size, overlapping the typical
duplication. The distal breakpoint of these atypical duplications
was located between 15.0–15.4 Mb and the proximal break-
point was located within a third LCR16 cluster (18.3–18.4 Mb).
Results of real-time qPCR with primer pair 2 (supplementary
table 2 online) were normal whereas the results using primer
pair 3 showed the presence of a duplication (fig 2). This result
confirms that the duplication starts in a more proximal LCR16
than the typical duplication. This duplicated region includes 12
RefSeq genes. The normal mother of patient 11 was found to be
a carrier of this same duplication.
One further patient (patient 13) carried a 1.6–2.1 Mb deletion
that flanked the common rearrangement region. This atypical
deletion had its distal breakpoint in the second cluster and its
proximal breakpoint in the third LCR16 cluster. The region
includes 2 RefSeq genes. This imbalance was inherited from a
phenotypically normal mother. A summary of all 13 rearrange-
ments found is shown in table 1.
DISCUSSION
We describe five patients carrying identical 1.65 Mb deletions of
16p13.11 encompassing 15 genes. In addition, we found five
patients carrying apparently reciprocal duplications of this same
region. The rearrangement breakpoints are located in low copy
repeats implying that non-allelic homologous recombination
between these flanking LCRs mediates these rearrangements.
Three further patients presenting with larger atypical rearrange-
ments showed breakpoints that also mapped to clusters of
LCR16.
Despite careful parental analysis, observations of rearrange-
ments of 16p13.11 make it difficult to distinguish between
disease-causing events (generally presumed to be de novo) and
benign variants (that do not contribute to a phenotype). Two
deletions and one duplication were found to be inherited from
an apparently normal parent, and another duplication was
inherited from a clinically mildly abnormal parent. Conversely,
we also found a duplication that occurred de novo. Previous
studies have reported 16p13.11 deletions occurring both de novo
and by inheritance from a normal parent, while duplications
were reported to be inherited from normal parents in two
families.
11 22 23 One interpretation of these observations could be
that rearrangements of this region are benign variants, and that
the observed phenotypes are coincidental with the presence of
the imbalance. However, one case–control study reported a
significantly higher incidence of the del16p13.11 in patients
with MR/MCA, implying that the del16p13.11 is a risk factor
contributing to the MR/MCA phenotype. The duplication is
present in equal frequency in the normal and the patient
population, indicating this variant is compatible with a normal
phenotype. The identification of this dup16p13.11 in a patient
with fragile X (patient 9) in our study lends support to this
hypothesis. Recently, Ullmann et al
11 reported three carriers of
dup16p13.11 in a cohort of 182 people with autism. Because the
duplication was found in 5 out of 2014 normal participants in
our study, the duplication seems overrepresented in the autistic
population (p=0.023, Fisher exact test). More studies are
needed strengthen this association.
Three of the four adult patients with 16p13.11 deletions had
both microcephaly and seizures, and the two fetuses with the
deletions had brain anomalies, one of which also had relative
microcephaly. The same three adult patients also have small
stature. Small stature and dysmorphic features were also a
feature of one of the patients described by Ullman et al.
11 In
contrast, our fourth adult patient and a previously described
deletion carrier
22 had normal head circumference (55.3 cm),
while one previously reported patient had macrocephaly.
11
Although the typical 16p13.11 duplication may be a benign
variant, it is striking that four of our duplication carriers not
only presented with MR but also behavioural problems.
Similarly, members of two of three families with duplications
reported by Ullman et al
11 had similar behavioural problems.
Although we do not have data on the behavioural phenotypes
of all patients with MR/MCA tested using the arrays, the
occurrence of this type of behaviour in this patient population
seems higher than average, and hence, it seems plausible that
dup16p13.11 carriers may have a predisposition for aggressive
behaviour.
To date, most genomic imbalances have been classified as
either benign or pathogenic and most microdeletion syndromes
are presumed to be well-defined clinical conditions. However,
even well-known genomic disorders can be phenotypically
heterogeneous and more variable than originally thought, owing
to incomplete penetrance or variable expression. The variability
Figure 2 Real-time quantitative PCR results with different primer sets
flanking the breakpoint regions. (A) In all individuals carrying the
common deletion/duplication (patients 1–10), the distal breakpoints
occur between primers pp1 and pp2, and the proximal breakpoint is
defined by primers pp4 and pp5. (B) The extent of the atypical
duplication and deletion identified in patients 11 and 13 were delineated
by primersets pp2/pp3 and pp4/pp5, respectively, for distal breakpoints
and between pp6 and pp7 for the proximal breakpoint. The presence of
two copies for a locus was defined by a fold difference of 1 whereas a
fold difference of 0.5 or 1.5 corresponds to a deletion or a duplication,
respectively.
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clinical classification as DiGeorge syndrome (heart and thymus
defects) (OMIM 188400), Sprintzen syndrome (speech difficul-
ties) or velocardiofacial syndrome (VCFS) (conotruncal anomaly
face) (OMIM 192430). Recently, several reports have been
published about atypical patients with 22q11 deletions.
24 25
Equally, in dup22q11 carriers, the phenotype may range from
severe MR through to completely unaffected, and various minor
developmental anomalies are noted.
26 27 In addition, 22q11
duplications can be inherited from apparently normal par-
ents.
26 28 Therefore, it is possible that 16p13.11 duplications
might also be causative and the heterogeneous phenotype of our
patients explained in part by (1) the unbiased selection criteria,
(2) variability due to other genetic or possibly environmental
determinants, (3) incomplete penetrance, (4) variable expression
or (5) unmasking of recessive alleles.
29 In particular, owing to
the presence of del16p13.11 in a normal parent of one of our
probands, we set out to test the latter hypothesis. Because
microcephaly was observed in two of the three adult patients
with typical deletions and in one of the two fetuses with
deletion, NDE1 was considered an excellent candidate gene for
this phenotype. NDE1 is strongly expressed in brain,
30 and
forms complexes with LIS1, a dosage-sensitive gene that is
crucial for neuronal migration and cerebral development, and
that is known to underlie Miller–Dieker lissencephaly syndrome
(OMIM 247200). Furthermore, Nde1-null mice show micro-
cephaly.
31 However, sequencing of all exons of NDE1 in four
patients with deletions did not reveal any mutation on the
remaining allele, suggesting that this is not the mechanism
responsible for the phenotype in our patients. Another plausible
candidate gene is NTAN1 (asparagine-specific N-terminal
amidase). Mouse models deficient for this enzyme showed
alterations in activity, social behaviour and memory.
32 However
although this region is reported in the Redon database (http://
projects.tcag.ca/variation/) to have CNVs, learning and mem-
ory defects and aberrant social behaviour could not be excluded
among controls and therefore the NTAN1 gene remains a good
candidate gene.
Imprinting is a mechanism that could potentially explain the
presence of these rearrangements in unaffected relatives.
11
However, there are no known imprinted genes on chromosome
16 (http://www.geneimprint.com/site/genes-by-species). Further-
more, for both deletions and duplications of 16p we observed the
inheritance of these imbalances from normal parents through
both the maternal and paternal germ lines, indicating that
imprinting does not significantly influence patient phenotype of
this disorder.
Inadditiontothecommon1.65 Mbrearrangementobservedin
the 10 patients reported here, 3 ‘‘atypical’’ chromosomal
imbalances either overlapping or flanking this common region
were found in patients with MR/MCA. Breakpoints for all three
imbalances were also located within LCR16 sequences. However,
theatypical3.4 Mbduplicationseemstobemediatedbydifferent
LCR16s compared with the atypical deletion. Therefore, the
complex structure of the LCR16s in this region seems to be
involved in generating a variety of different chromosomal
Figure 3 Detection of 16p12–p13 imbalances defined by the 262k NspI SNP array. Data from the common 16p13.11 1.65 Mb rearrangements are
shown. Each plot has physical probe position on 16p (x-axis) against probe intensity ratio (y-axis). Red shading, common deleted region; green shading,
duplication in patients 1–4, 6 and 7. Chr, chromosome.
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chromosome 16p is similar to that observed for other recurrent
genomic disorders, such as the Prader–Willi/Angelman
syndrome,
33 Smith–Magenis syndrome,
34 and the 15q24 deletion
syndrome,
35 in which recombination within alternate LCRs can
result in recurrent deletions and duplications of different sizes.
Figure 4 High-resolution oligonucleotide array mapping of seven 16p12.3–p13.11 rearrangements, of which four have a common distal breakpoint
(14.7–14.75 Mb). For those four patients with the common 1.65 Mb rearrangement (red shading), the proximal breakpoints also map to a second
LCR16 cluster (16.3–16.77 Mb). Another three patients have an atypical rearrangement: patients 11 and 12 show an atypical larger duplication, with
the distal breakpoint between 15.0–15.4 Mb and the proximal breakpoint located within a third LCR16 cluster (18.3–18.4 Mb), and patient 13 has an
atypical deletion with proximal breakpoint in the third LCR16 cluster and distal breakpoint in the second cluster. Data from normal control individuals
show that there is marked copy number variation in the LCR16 clusters that define these three breakpoint regions. Note that the high degree of
homology between these LCR16s also results in false-positive signals from probes that are identical to those within the true deletion/duplication in
patients 5, 8 and 9. The image has a 5 Mb region of 16p12–p13 (chr16:14 000 000–19 000 000). For each individual, deviations of probe log2 ratios
from zero are depicted by grey/black lines, with those exceeding a threshold of 1.5 SD from the mean probe ratio shown in green and red to represent
relative gains and losses, respectively. Segmental duplications of increasing similarity (90–98%, 98–99%, and .99%) are represented by grey/yellow/
orange bars, respectively.
Original article
J Med Genet 2009;46:223–232. doi:10.1136/jmg.2007.055202 229In conclusion, we report a novel genomic disorder likely
caused by NAHR between copies of LCR16. Although in some
cases this is inherited from a normal parent, we found a
strong association of the deletion with developmental
disorders. Reciprocal duplications were observed as both
inherited and de novo events, and were also identified in
several controls, suggesting that the duplication by itself
confers either no phenotype at all or a range of phenotypes of
varying severity. Alternatively, the duplication may require
additional predisposing factors to have a phenotypic effect.
Our findings have important implications for genetic counsel-
ling. Traditionally, chromosomal imbalances inherited from a
normal parent were considered benign, while de novo
chromosomal imbalances were considered pathogenic.
Although our results suggest that the inherited 16p13.11
deletion is likely causal for the phenotype, the clinical
significance of both de novo and inherited duplications
remains uncertain and they may be benign variants. The
study of additional patients and normal individuals with
16p13.11 rearrangements is required to reinforce this
hypothesis and to obtain better insight in the potential
pathology associated with the observed microdeletion and
microduplication events.
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Table 1 Genotype–phenotype correlation of patients with deletion or duplication of 16p12–p13
Patient (Deciphercode) Phenotype Pattern of inheritance
Type of
imbalance
Distal
breakpoint (Mb)
Proximal
breakpoint (Mb)
1 (CHG00002371) Severe MR, IQ=38, short stature (143 cm), microcephaly (51 cm),
epilepsy, ataxia
Parents not available
for testing
Deletion 14.7–14.75 16.3–16.77
2 (CHG00002372) Severe MR, short stature (150 cm), microcephaly (51 cm), epilepsy,
pectus excavatum, limb spasticity
Affected brother does
not carry deletion
14.7–14.75 16.3–16.77
Parents not available
for testing
3 (CHG00002374–) Moderate MR, normal stature (183 cm), normal head circumference
(55,3 cm), behavioural problems
Parents not available
for testing
14.7–14.75 16.3–16.77
4 (CHG00001230) Term fetus; autopsy showed holoprosencephaly, nose agenesis, midline
upper lip notch, midline cleft palate, dysplastic external ear and atretic
auditory canal on right, preauricular skin tags bilaterally, relative
microcephaly
Phenotypically normal
father carries deletion
14.7–14.75 16.3–16.77
5 Fetus at 21 weeks; autopsy showed post-hemorrhagic hydrocephalus
with marked ventriculomegaly, cortical thinning, hypoplastic falx cerebri,
cleft lip on right, two preauricular skin tags on right, and cleft T1 and T3
vertebral bodies. Physical growth parameters were consistent with
gestational age
Parents not available
for testing
14.7–14.75 16.3–16.77
6 (CHG00001046) Moderate MR, normal stature (176 cm), normal head circumference
(57.4 cm), behavioural problems, Hirschsprung disease
Mother does not carry
duplication
Duplication 14.7–14.75 16.3–16.77
Father unavailable for
testing
7 (LEI)00002370) MR, mild developmental delay, learning disabilities. Originally reported by
Kriek et al.
9
de novo imbalance 14.7–14.75 16.3–16.77
8 Severe learning disabilities with limited use of language, poor vocabulary
and repetitive speech, epilepsy. Challenging, agitated behaviour marked
by shouting, hand-clapping, kicking, hitting and throwing objects at
people, although this has improved with age
Phenotypically normal
father carries
duplication
14.7–14.75 16.3–16.77
9 Moderate developmental delay, behavioural problems (increased
impulsivity, limited attention span). Large simple ears, thick lips, large
tongue, large puffy hands and small nails. Also has an expansion of the
FRAXA triplet repeat
Parents not available
for testing
14.7–14.75 16.3–16.77
10 Microcephaly found at 20 weeks gestation. At 4 years of age OFC 44 cm
(P3=48.6 cm). Brachycephaly, telecanthus, abnormal eyebrows, deep
set eyes, epicanthic folds, pinched nasal tip, prominent nose, small jaw,
VSD, umbilical hernia, deep palmar and plantar creases, speech delay,
hyperactive behavioural with aggressive episodes. Mother has small head
(no OFC)
Mother with mild
phenotype carries the
duplication
14.7–14.75 16.3–16.77
11 (CHG00000993) Feeding and respiratory problems as neonate. Asymmetric face with left
facial nerve paresis, short neck with reduced mobility, bilateral epicanthal
folds, strabismus, choroid colobomata, atresia of right choana, ASDII,
unique right kidney with double ureters, aplasia of semicircular canals,
abnormal middle ear bones
Phenotypically normal
mother carries
duplication
Duplication 15.1–15.4 18.05–18.45
12 MR, multiple congenital anomalies. Originally reported by Sharp et al.
10 Parents not available
for testing
15.1–15.4 18.3–18.5
13 (CHG00002373) Marked developmental delay, IQ=38, short stature (150 cm),
microcephaly (50,5 cm), neonatal seizures
Phenotypically normal
mother carries deletion
Deletion 16.3–16.77 18.3–18.4
MR, mental retardation; OFC, occiptofrontal circumference.
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